We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
(+100,205%)
Cap. Flow
-$417M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$89.3M |
| 2 |
Keysight
KEYS
|
+$86M |
| 3 |
Nike
NKE
|
+$78.3M |
| 4 |
Amphenol
APH
|
+$76.5M |
| 5 |
Comcast
CMCSA
|
+$72.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celanese
CE
|
+$108M |
| 2 |
Monster Beverage
MNST
|
+$97.8M |
| 3 |
Starbucks
SBUX
|
+$79.7M |
| 4 |
Texas Instruments
TXN
|
+$67.3M |
| 5 |
Centene
CNC
|
+$64.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.83% |
| 2 | Financials | 13.42% |
| 3 | Healthcare | 13.25% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
TE Connectivity
TEL
$59.2B
| $8.63M | 0.04% |
90,081
-3,566
| -4% | -$330K |
|
352
Fox Class A
FOXA
$23.9B
| $8.59M | 0.04% |
231,858
+117,531
| +103% | +$4.02M |
|
353
Vanguard Total World Stock ETF
VT
$76.2B
| $8.55M | 0.04% |
105,543
+90,477
| +601% | +$7.04M |
|
354
Becton Dickinson
BDX
$44B
| $8.38M | 0.04% |
31,604
+635
| +2% | +$158K |
|
355
US Commodity Index
USCI
$366M
| $8.11M | 0.04% |
219,836
-384,516
| -64% | -$13.9M |
|
356
Northrop Grumman
NOC
$77.9B
| $8.02M | 0.04% |
23,305
+11,750
| +102% | +$4.13M |
|
357
Nucor
NUE
$55.8B
| $7.97M | 0.04% |
141,653
+68,777
| +94% | +$3.75M |
|
358
Danaher
DHR
$137B
| $7.97M | 0.04% |
58,577
+4,114
| +8% | +$520K |
|
359
Invesco FTSE RAFI US 1000 ETF
PRF
$9.75B
| $7.95M | 0.04% |
313,920
-4,230
| -1% | -$103K |
|
|
PXD
360
DELISTED
Pioneer Natural Resource Co.
PXD
| $7.95M | 0.04% |
52,553
-49,191
| -48% | -$6.55M |
|
361
iShares Russell 1000 Value ETF
IWD
$81.4B
| $7.89M | 0.04% |
57,810
-161
| -0.3% | -$21.2K |
|
362
WPP
WPP
$4.24B
| $7.79M | 0.04% |
110,784
+24,964
| +29% | +$1.58M |
|
363
iShares Russell 1000 ETF
IWB
$47.7B
| $7.77M | 0.04% |
43,551
-508
| -1% | -$86.7K |
|
364
Euronet Worldwide
EEFT
$3.03B
| $7.72M | 0.04% |
49,015
+6,227
| +15% | +$940K |
|
365
AstraZeneca
AZN
$263B
| $7.68M | 0.04% |
77,002
+440
| +0.6% | +$41.4K |
|
366
Invesco QQQ Trust
QQQ
$447B
| $7.62M | 0.03% |
35,848
-316
| -0.9% | -$63.3K |
|
367
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$26.8B
| $7.59M | 0.03% |
20,232
-972
| -5% | -$351K |
|
368
Goldman Sachs
GS
$304B
| $7.52M | 0.03% |
32,698
+1,866
| +6% | +$405K |
|
369
Progressive
PGR
$126B
| $7.45M | 0.03% |
102,964
-12,385
| -11% | -$893K |
|
|
PPL
370
PPL Corp
PPL
$27.1B
| $7.35M | 0.03% |
204,990
+2,584
| +1% | +$86.6K |
|
371
iShares Russell 2000 Value ETF
IWN
$14.4B
| $7.25M | 0.03% |
56,370
-14
| -0% | -$1.73K |
|
372
Diageo
DEO
$47.6B
| $7.22M | 0.03% |
42,875
-2,492
| -5% | -$405K |
|
373
Zoetis
ZTS
$32.4B
| $7.18M | 0.03% |
54,242
+1,581
| +3% | +$196K |
|
374
Pinnacle West Capital
PNW
$12.8B
| $6.96M | 0.03% |
77,464
-3,826
| -5% | -$345K |
|
375
CenterPoint Energy
CNP
$28.8B
| $6.92M | 0.03% |
253,695
-480,853
| -65% | -$13.1M |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q4 2019 Portfolio in Review
As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
- Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
- Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
- Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
- Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
- Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
- Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
- Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.
Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.